{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:40:26Z","timestamp":1784677226924,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10147-021-02103-7","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T08:03:17Z","timestamp":1641369797000},"page":"790-801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2717-2780","authenticated-orcid":false,"given":"Hiroki","family":"Nasu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongmyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruyuki","family":"Yoshimitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Matsukuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Tasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Katsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsumu","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotake","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimio","family":"Ushijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"2103_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"2103_CR2","unstructured":"National Cancer Registry (Ministry of Health, Labour and Welfare), tabulated by Cancer Information Service, National Cancer Center, Japan. https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html"},{"key":"2103_CR3","unstructured":"Vital Statistics in Japan, tabulated by Cancer Information Service, National Cancer Center, Japan. https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html"},{"key":"2103_CR4","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC et al (2014) Ovarian cancer. Lancet 384:1376\u20131388. https:\/\/doi.org\/10.1016\/S0140-6736(13)62146-7","journal-title":"Lancet"},{"key":"2103_CR5","doi-asserted-by":"publisher","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","volume":"28","author":"S Pignata","year":"2017","unstructured":"Pignata S, Cecere SC, Du Bois A et al (2017) Treatment of recurrent ovarian cancer. Ann Oncol 28:viii51\u2013viii56. https:\/\/doi.org\/10.1093\/annonc\/mdx441","journal-title":"Ann Oncol"},{"key":"2103_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/497429","author":"K Ushijima","year":"2010","unstructured":"Ushijima K (2010) Treatment for recurrent ovarian cancer\u2014at first relapse. J Oncol. https:\/\/doi.org\/10.1155\/2010\/497429","journal-title":"J Oncol"},{"key":"2103_CR7","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T et al (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811\u20132818. https:\/\/doi.org\/10.1200\/JCO.2006.09.6735","journal-title":"J Clin Oncol"},{"key":"2103_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","volume":"95","author":"AN Gordon","year":"2004","unstructured":"Gordon AN, Tonda M, Sun S et al (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2004.07.011","journal-title":"Gynecol Oncol"},{"key":"2103_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/annonc\/mdh025","volume":"15","author":"HW ten Bokkel","year":"2004","unstructured":"ten Bokkel HW, Lane SR, Ross GA (2004) Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15:100\u2013103. https:\/\/doi.org\/10.1093\/annonc\/mdh025","journal-title":"Ann Oncol"},{"key":"2103_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","volume":"16","author":"PG Rose","year":"1998","unstructured":"Rose PG, Blessing JA, Mayer AR et al (1998) Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 16:405\u2013410. https:\/\/doi.org\/10.1200\/JCO.1998.16.2.405","journal-title":"J Clin Oncol"},{"key":"2103_CR11","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302\u20131308. https:\/\/doi.org\/10.1200\/JCO.2013.51.4489","journal-title":"J Clin Oncol"},{"key":"2103_CR12","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1093\/carcin\/16.10.2447","volume":"16","author":"AMJ Flchtlnger-Schepman","year":"1995","unstructured":"Flchtlnger-Schepman AMJ, Van Dijk-knijnenburg HCM, Van Der Velde-visser SD et al (1995) Cisplatin- and carboplatin-DNA adducts: is pt-ag the cytotoxic lesion? Carcinogenesis 16:2447\u20132453. https:\/\/doi.org\/10.1093\/carcin\/16.10.2447","journal-title":"Carcinogenesis"},{"key":"2103_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(01)00454-5","volume":"2","author":"PJ McHugh","year":"2001","unstructured":"McHugh PJ, Spanswick VJ, Hartley JA (2001) Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2:483\u2013490. https:\/\/doi.org\/10.1016\/S1470-2045(01)00454-5","journal-title":"Lancet Oncol"},{"key":"2103_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/sj.bjc.6603973","volume":"97","author":"P Wynne","year":"2007","unstructured":"Wynne P, Newton C, Ledermann JA et al (2007) Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer 97:927\u2013933. https:\/\/doi.org\/10.1038\/sj.bjc.6603973","journal-title":"Br J Cancer"},{"key":"2103_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0090-8258(03)00011-8","volume":"88","author":"G D\u2019Agostino","year":"2003","unstructured":"D\u2019Agostino G, Amant F, Berteloot P et al (2003) Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 88:266\u2013269. https:\/\/doi.org\/10.1016\/S0090-8258(03)00011-8","journal-title":"Gynecol Oncol"},{"key":"2103_CR16","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1158\/1078-0432.CCR-10-0832","volume":"16","author":"JA Ledermann","year":"2010","unstructured":"Ledermann JA, Gabra H, Jayson GC et al (2010) Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Clin Cancer Res 16:4899\u20134905. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0832","journal-title":"Clin Cancer Res"},{"key":"2103_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00280-020-04162-5","volume":"86","author":"MKG Hansen","year":"2020","unstructured":"Hansen MKG, Smerdel MP, Waldstr\u00f8m M et al (2020) Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients. Cancer Chemother Pharmacol 86:751\u2013759. https:\/\/doi.org\/10.1007\/s00280-020-04162-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"2103_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2103_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"G John","year":"2011","unstructured":"John G, Rustin S, Vergote I et al (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG). Int J Gynecol Cancer 21:419\u2013423. https:\/\/doi.org\/10.1097\/IGC.0b013e3182070f17","journal-title":"Int J Gynecol Cancer"},{"key":"2103_CR20","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756. https:\/\/doi.org\/10.1200\/JCO.1989.7.11.1748","journal-title":"J Clin Oncol"},{"key":"2103_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341. https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron"},{"key":"2103_CR22","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039\u20132045. https:\/\/doi.org\/10.1200\/JCO.2012.42.0505","journal-title":"J Clin Oncol"},{"key":"2103_CR23","unstructured":"Greenwood M (1926) The natural duration of cancer. Reports on Public Health and Medical Subjects. London: Her Majesty's Stationery Office. 33:1\u201326"},{"key":"2103_CR24","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","volume":"26","author":"G Ferrandina","year":"2008","unstructured":"Ferrandina G, Ludovisi M, Lorusso D et al (2008) Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26:890\u2013896. https:\/\/doi.org\/10.1200\/JCO.2007.13.6606","journal-title":"J Clin Oncol"},{"key":"2103_CR25","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ygyno.2006.03.018","volume":"103","author":"CA Brewer","year":"2006","unstructured":"Brewer CA, Blessing JA, Nagourney RA et al (2006) Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 103:446\u2013450. https:\/\/doi.org\/10.1016\/j.ygyno.2006.03.018","journal-title":"Gynecol Oncol"},{"key":"2103_CR26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/sj.bjc.6604914","volume":"100","author":"R Sharma","year":"2009","unstructured":"Sharma R, Graham J, Mitchell H et al (2009) Extended weekly dose-dense paclitaxel\/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 100:707\u2013712. https:\/\/doi.org\/10.1038\/sj.bjc.6604914","journal-title":"Br J Cancer"},{"key":"2103_CR27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/annonc\/mdr149","volume":"23","author":"A Lortholary","year":"2012","unstructured":"Lortholary A, Largillier R, Weber B et al (2012) Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from groupe d\u2019investigateurs nationaux pour l\u2019etude des cancers ovariens (GINECO). Ann Oncol 23:346\u2013352. https:\/\/doi.org\/10.1093\/annonc\/mdr149","journal-title":"Ann Oncol"},{"key":"2103_CR28","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/sj.bjc.6601787","volume":"90","author":"I Oncologico","year":"2004","unstructured":"Oncologico I, Buda A, Floriani I et al (2004) Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian collaborative study from the \u201cMario Negri\u201d Institut. Br J Cancer 90:2112\u20132117. https:\/\/doi.org\/10.1038\/sj.bjc.6601787","journal-title":"Br J Cancer"},{"key":"2103_CR29","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","volume":"26","author":"J Sehouli","year":"2008","unstructured":"Sehouli J, Stengel D, Oskay-oezcelik G et al (2008) Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26:3176\u20133182. https:\/\/doi.org\/10.1200\/JCO.2007.15.1258","journal-title":"J Clin Oncol"},{"key":"2103_CR30","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00280-018-3552-5","volume":"81","author":"K Takasaki","year":"2018","unstructured":"Takasaki K, Miyamoto M, Takano M et al (2018) Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis. Cancer Chemother Pharmacol 81:809\u2013814. https:\/\/doi.org\/10.1007\/s00280-018-3552-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"2103_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-020-0617-y","volume":"13","author":"S Nagao","year":"2020","unstructured":"Nagao S, Kogiku A, Suzuki K et al (2020) A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Ovarian Res 13:1\u20136. https:\/\/doi.org\/10.1186\/s13048-020-0617-y","journal-title":"J Ovarian Res"},{"key":"2103_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s10147-014-0731-1","volume":"20","author":"N Takase","year":"2015","unstructured":"Takase N, Matsumoto K, Onoe T et al (2015) 4-Step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. Int J Clin Oncol 20:566\u2013573. https:\/\/doi.org\/10.1007\/s10147-014-0731-1","journal-title":"Int J Clin Oncol"},{"key":"2103_CR33","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1634\/theoncologist.2018-0167","volume":"23","author":"Y Inayama","year":"2018","unstructured":"Inayama Y, Hamanishi J, Matsumura N et al (2018) Antitumor effect of nivolumab on subsequent chemotherapy for platinum-resistant ovarian cancer. Oncologist 23:1382\u20131384. https:\/\/doi.org\/10.1634\/theoncologist.2018-0167","journal-title":"Oncologist"},{"key":"2103_CR34","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T et al (2015) Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33:4015\u20134022. https:\/\/doi.org\/10.1200\/JCO.2015.62.3397","journal-title":"J Clin Oncol"},{"key":"2103_CR35","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Santin AD, Lisyanskaya AS et al (2019) Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol 30:1080\u20131087. https:\/\/doi.org\/10.1093\/annonc\/mdz135","journal-title":"Ann Oncol"},{"key":"2103_CR36","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","volume":"5","author":"JF Liu","year":"2019","unstructured":"Liu JF, Herold C, Gray KP et al (2019) Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial. JAMA Oncol 5:1731\u20131738. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3343","journal-title":"JAMA Oncol"},{"key":"2103_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","volume":"140","author":"SM Domchek","year":"2016","unstructured":"Domchek SM, Aghajanian C, Shapira-frommer R et al (2016) Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol 140:199\u2013203. https:\/\/doi.org\/10.1016\/j.ygyno.2015.12.020","journal-title":"Gynecol Oncol"},{"key":"2103_CR38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","volume":"21","author":"J Pfisterer","year":"2020","unstructured":"Pfisterer J, Shannon CM, Baumann K et al (2020) Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol 21:699\u2013709. https:\/\/doi.org\/10.1016\/S1470-2045(20)30142-X","journal-title":"Lancet Oncol"},{"key":"2103_CR39","doi-asserted-by":"publisher","first-page":"S627","DOI":"10.1016\/j.annonc.2020.08.973","volume":"31","author":"K Ito","year":"2020","unstructured":"Ito K, Nakagawa M, Hori K et al (2020) 834P A phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear-cell carcinoma (KCOG-G1601 trial). Ann Oncol 31:S627. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.973","journal-title":"Ann Oncol"},{"key":"2103_CR40","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","volume":"33","author":"AM Poveda","year":"2015","unstructured":"Poveda AM, Selle F, Hilpert F et al (2015) Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III aurelia trial. J Clin Oncol 33:3836\u20133838. https:\/\/doi.org\/10.1200\/JCO.2015.63.1408","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02103-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-021-02103-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02103-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T18:24:32Z","timestamp":1648232672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-021-02103-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2103"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-02103-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]},"assertion":[{"value":"14 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}